MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100037-PIP01-21-M01)

MHRA-100037-PIP01-21-M02

Scope of the Application

Active Substance(s)

PONESIMOD

Condition(s)

Treatment of Multiple Sclerosis

Pharmaceutical Form(s)

Film-coated tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Janssen-Cilag Ltd

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Janssen-Cilag Ltd submitted to the licensing authority on 11/08/2023 16:03 BST an application for a Modification

The procedure started on 01/12/2023 09:49 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100037-PIP01-21-M02

Of 19/12/2023 10:44 GMT

On the adopted decision for PONESIMOD (MHRA-100037-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for PONESIMOD, Film-coated tablet , ORAL USE .

This decision is addressed to Janssen-Cilag Ltd, 50-100 Holmers Farm Way, Buckinghamshire, High Wycombe, UNITED KINGDOM, HP12 4EG

ANNEX I

1. Waiver

1.1 Condition:

Treatment of multiple sclerosis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 10 years of age Pharmaceutical form(s): Film-coated tablet Route(s) of administration: Oral use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of multiple sclerosis

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients with relapsing-remitting multiple sclerosis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 10 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	1	Study 1 Nine (9) week repeated dose oral juvenile toxicity study of ponesimod in 4 week old rats, with a 4 week recovery period.
Clinical Studies	1	Study 2 Multi-centre, randomised, double-blind, active controlled, study to evaluate the pharmacokinetics, pharmacodynamics, efficacy and safety of ponesimod versus fingolimod during 108 weeks of treatment in paediatric patients from 10 years to less than 18 years of age with relapsing-remitting multiple sclerosis (RRMS).
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/11/2027
Deferral of one or more studies contained in the paediatric investigation plan:	Yes